TC

19/02/2020 11:49

{I-bank focus}BofA raises WuXi Biologics (02269) to HK$129

    BofA Global Research upped its target price for WuXi Biologics (02269) to HK$129 from HK$117 and maintained its "buy" rating.
  In addition to Gloria's PD-1 GLS-010 and Amicus' ATB200 for which WuXi Bio would be
a commercial manufacturer, the research house thinks WuXi is also manufacturing clinical trial material for GSK's PD-1 TSR042, CStone's PD-L1 CS1001, Acrus' PD-1 AB122, Momenta's FcRn antibody M281 and Eylea biosimilar M710, Immutep's LAG-3 antibody IMP321, InflaRx's IFX-1.
  BofA believes WuXi Bio could become a commercial manufacturer for those drugs' as
well. In particular, there could be catalysts in addition to the WuXi Vaccine contract
signing: IMP321 Ph2 combo data in 1L NSCLC on 19 February and Ph2 combo data in mBC in
1Q 2020, M281 Ph2 data in generalized myasthenia gravis in 3Q 2020, CS1001 NDA filing in China, and WuXi's 2019-nCoV neutralizing antibody development achievements.

人氣文章
財經新聞
評論
專題
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【嚴正聲明】《經濟通》呼籲公眾提高警覺留意偽冒《經濟通》投資群組

如何分辨問米是否真實?通靈問事用什麼工具都可以?靈靈法即場示範通靈!

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

Watche Trends 2024

北上食買玩

Art Month 2024

理財秘笈

夏天養生食療

消委會報告

山今養生智慧

輕鬆護老